{"id":67124,"date":"2026-05-20T12:32:35","date_gmt":"2026-05-20T07:02:35","guid":{"rendered":"https:\/\/www.equentis.com\/blog\/?p=67124"},"modified":"2026-05-20T12:32:37","modified_gmt":"2026-05-20T07:02:37","slug":"zydus-lifesciences-announces-%e2%82%b91100-crore-share-buyback-at-13-premium-record-date-and-key-details-inside","status":"publish","type":"post","link":"https:\/\/www.equentis.com\/blog\/zydus-lifesciences-announces-%e2%82%b91100-crore-share-buyback-at-13-premium-record-date-and-key-details-inside\/","title":{"rendered":"Zydus Lifesciences Announces \u20b91,100 Crore Share Buyback At 13% Premium; Record Date And Key Details Inside"},"content":{"rendered":"
<\/div>\n

Summary<\/strong><\/h2>\n\n\n\n

Zydus Lifesciences has announced a \u20b91,100 crore share buyback at a 13% premium to the prevailing market price, attracting strong attention from investors across the Indian stock market. The company plans to repurchase shares from eligible shareholders through the tender offer route, with the buyback aimed at improving shareholder value, optimizing capital allocation, and signaling confidence in its long-term growth prospects. Investors are now closely watching the record date, eligibility criteria, buyback ratio, and the potential impact on Zydus Lifesciences’ share price in the coming months.<\/p>\n\n\n\n

Why Zydus Lifesciences\u2019 Buyback Announcement Matters<\/strong><\/h2>\n\n\n\n

Share buybacks often create excitement in the market, especially when they are announced at a premium. In the case of Zydus Lifesciences, the \u20b91,100 crore buyback has become a major talking point because it comes at a time when pharmaceutical companies are navigating a mix of global opportunities and pricing pressures.<\/p>\n\n\n\n

For retail investors, buybacks are not just corporate announcements. They can influence stock prices, improve investor sentiment, and provide an opportunity to exit holdings at attractive valuations.<\/p>\n\n\n\n

The Zydus Lifesciences buyback also signals management confidence in the company\u2019s financial health and future earnings visibility. When a company chooses to deploy cash reserves toward repurchasing shares, it usually reflects a belief that the stock may be undervalued or that returning capital to shareholders is the best use of funds.<\/p>\n\n\n\n

Understanding the Zydus Lifesciences Share Buyback<\/strong><\/h2>\n\n\n\n

A share buyback occurs when a company repurchases its own shares from shareholders. This reduces the number of shares available in the market and can improve earnings per share over time.<\/p>\n\n\n\n

In this case, Zydus Lifesciences announced:<\/p>\n\n\n\n

    \n
  • A buyback size of \u20b91,100 crore<\/li>\n\n\n\n
  • A buyback price at around 13% premium<\/li>\n\n\n\n
  • Repurchase through the tender offer route<\/li>\n\n\n\n
  • Participation eligibility based on the record date<\/li>\n<\/ul>\n\n\n\n

    The tender offer method allows eligible shareholders to tender their shares directly to the company during the buyback window.<\/p>\n\n\n\n

    Key Details Investors Should Know<\/strong><\/h2>\n\n\n\n

    Buyback Size<\/strong><\/h3>\n\n\n\n

    The \u20b91,100 crore buyback reflects a sizeable capital return initiative by the company. Large buyback programs are generally viewed positively because they indicate strong balance sheet strength and healthy cash generation.<\/p>\n\n\n\n

    Buyback Premium<\/strong><\/h3>\n\n\n\n

    The company announced the repurchase price at a premium of around 13% over the prevailing market price.<\/p>\n\n\n\n

    A premium matters because:<\/p>\n\n\n\n

      \n
    • It incentivizes shareholders to participate<\/li>\n\n\n\n
    • It often supports stock market sentiment<\/li>\n\n\n\n
    • It reflects management confidence<\/li>\n<\/ul>\n\n\n\n

      For short-term traders, premium-based buybacks can create price momentum around the stock.<\/p>\n\n\n\n

      Record Date<\/strong><\/h3>\n\n\n\n

      The record date is critical because it determines shareholder eligibility for participating in the buyback.<\/p>\n\n\n\n

      Investors holding shares before the ex-date associated with the record date generally become eligible to tender shares in the buyback offer.<\/p>\n\n\n\n

      This is why trading activity in stocks often increases around buyback announcements and record dates.<\/p>\n\n\n\n

      Tender Offer Route<\/strong><\/h3>\n\n\n\n

      Under the tender offer mechanism:<\/p>\n\n\n\n

        \n
      • Eligible shareholders can offer shares back to the company<\/li>\n\n\n\n
      • The company accepts shares based on entitlement ratios and demand<\/li>\n\n\n\n
      • Accepted shares are bought at the buyback price<\/li>\n<\/ul>\n\n\n\n

        This route is popular among Indian companies because it allows participation from retail investors.<\/p>\n\n\n\n

        Background of Zydus Lifesciences<\/strong><\/h2>\n\n\n\n

        Zydus Lifesciences is one of India\u2019s major pharmaceutical companies with a presence across:<\/p>\n\n\n\n

          \n
        • Generic medicines<\/li>\n\n\n\n
        • Specialty drugs<\/li>\n\n\n\n
        • Vaccines<\/li>\n\n\n\n
        • Biosimilars<\/li>\n\n\n\n
        • Consumer wellness products<\/li>\n<\/ul>\n\n\n\n

          The company has expanded significantly over the years through research investments, international market expansion, and product diversification.<\/p>\n\n\n\n

          Earlier known as Cadila Healthcare, the company rebranded itself as Zydus Lifesciences to align with its broader healthcare and innovation-focused strategy.<\/p>\n\n\n\n

          Today, it operates in multiple international markets, including the United States, Europe, Latin America, and emerging economies.<\/p>\n\n\n\n

          Why Companies Announce Share Buybacks<\/strong><\/h2>\n\n\n\n

          The Zydus buyback also raises a broader question: why do companies buy back shares?<\/p>\n\n\n\n

          There are several reasons.<\/p>\n\n\n\n

          Returning Excess Cash to Shareholders<\/strong><\/h3>\n\n\n\n

          Companies with strong cash reserves sometimes prefer buybacks over dividends because buybacks can improve shareholder value without committing to recurring payouts.<\/p>\n\n\n\n

          Improving Earnings Per Share<\/strong><\/h3>\n\n\n\n

          When the number of outstanding shares decreases, earnings per share may improve even if profits remain stable.<\/p>\n\n\n\n

          Higher EPS often improves investor perception.<\/p>\n\n\n\n

          Signaling Confidence<\/strong><\/h3>\n\n\n\n

          Management announcing a buyback may indicate confidence in:<\/p>\n\n\n\n

            \n
          • Future growth<\/li>\n\n\n\n
          • Profitability<\/li>\n\n\n\n
          • Cash flows<\/li>\n\n\n\n
          • Business stability<\/li>\n<\/ul>\n\n\n\n

            Supporting Share Price<\/strong><\/h3>\n\n\n\n

            Buybacks can help stabilize or support stock prices during periods of volatility.<\/p>\n\n\n\n

            Market Reaction to the Announcement<\/strong><\/h2>\n\n\n\n

            The market generally reacts positively to buybacks announced at premiums because investors see immediate value in the offer price.<\/p>\n\n\n\n

            Following the announcement, investor attention toward Zydus Lifesciences increased significantly.<\/p>\n\n\n\n

            Several factors influenced sentiment:<\/p>\n\n\n\n

              \n
            • Attractive premium<\/li>\n\n\n\n
            • Strong pharmaceutical sector outlook<\/li>\n\n\n\n
            • Healthy financial position<\/li>\n\n\n\n
            • Confidence in long-term business growth<\/li>\n<\/ul>\n\n\n\n

              Analysts also noted that buybacks often improve return ratios and capital efficiency metrics.<\/p>\n\n\n\n

              What the Buyback Means for Retail Investors<\/strong><\/h2>\n\n\n\n

              Retail investors are among the biggest beneficiaries of tender offer buybacks in India.<\/p>\n\n\n\n

              Opportunity to Exit at Premium Pricing<\/strong><\/h3>\n\n\n\n

              Eligible shareholders may tender shares at the buyback price, which is usually higher than the prevailing market price.<\/p>\n\n\n\n

              This creates a potential opportunity for gains.<\/p>\n\n\n\n

              Improved Shareholder Value<\/strong><\/h3>\n\n\n\n

              Reducing outstanding shares may improve future earnings per share and return ratios.<\/p>\n\n\n\n

              Increased Stock Visibility<\/strong><\/h3>\n\n\n\n

              Buybacks often attract market attention, increasing trading activity and investor interest.<\/p>\n\n\n\n

              However, investors should also understand that not all tendered shares may be accepted due to entitlement ratios and oversubscription.<\/p>\n\n\n\n

              Understanding Entitlement Ratio and Acceptance Ratio<\/strong><\/h2>\n\n\n\n

              These are two important concepts in any buyback.<\/p>\n\n\n\n

              Entitlement Ratio<\/strong><\/h3>\n\n\n\n

              This refers to the number of shares a shareholder is eligible to tender based on holdings as of the record date.<\/p>\n\n\n\n

              Acceptance Ratio<\/strong><\/h3>\n\n\n\n

              This refers to the percentage of tendered shares actually accepted by the company.<\/p>\n\n\n\n

              If the buyback is heavily oversubscribed, acceptance ratios may decline.<\/p>\n\n\n\n

              Retail participation levels often influence final acceptance rates.<\/p>\n\n\n\n

              Broader Trends in the Indian Pharmaceutical Sector<\/strong><\/h2>\n\n\n\n

              The Zydus buyback announcement also comes during an interesting phase for the Indian pharmaceutical industry.<\/p>\n\n\n\n

              Strong Export Opportunities<\/strong><\/h2>\n\n\n\n

              Indian pharma companies continue benefiting from strong global demand for generic medicines and affordable healthcare products.<\/p>\n\n\n\n

              The United States remains a key export market.<\/p>\n\n\n\n

              Focus on Innovation<\/strong><\/h3>\n\n\n\n

              Companies are increasingly investing in:<\/p>\n\n\n\n

                \n
              • Specialty drugs<\/li>\n\n\n\n
              • Biologics<\/li>\n\n\n\n
              • Vaccines<\/li>\n\n\n\n
              • Complex generics<\/li>\n<\/ul>\n\n\n\n

                This shift is gradually improving long-term growth potential.<\/p>\n\n\n\n

                Domestic Healthcare Growth<\/strong><\/h3>\n\n\n\n

                Rising healthcare awareness and increasing medical access are supporting growth in India\u2019s domestic pharmaceutical market.<\/p>\n\n\n\n

                Challenges Facing Pharma Companies<\/strong><\/h2>\n\n\n\n

                Despite growth opportunities, the sector also faces several risks.<\/p>\n\n\n\n

                USFDA Regulatory Scrutiny<\/strong><\/h3>\n\n\n\n

                Pharmaceutical companies with US exposure must comply with strict regulatory standards.<\/p>\n\n\n\n

                Any warning letters or compliance issues can impact operations and investor sentiment.<\/p>\n\n\n\n

                Pricing Pressure<\/strong><\/h3>\n\n\n\n

                Generic drug pricing pressure remains a challenge globally, especially in the US market.<\/p>\n\n\n\n

                Currency Volatility<\/strong><\/h3>\n\n\n\n

                Export-focused companies are influenced by currency fluctuations.<\/p>\n\n\n\n

                Research and Development Costs<\/strong><\/h3>\n\n\n\n

                Innovation requires significant investment, and outcomes are not always predictable.<\/p>\n\n\n\n

                How Zydus Lifesciences Has Positioned Itself<\/strong><\/h2>\n\n\n\n

                Zydus Lifesciences has attempted to diversify beyond traditional generic drugs.<\/p>\n\n\n\n

                The company has expanded into:<\/p>\n\n\n\n

                  \n
                • Biosimilars<\/li>\n\n\n\n
                • Vaccines<\/li>\n\n\n\n
                • Consumer healthcare<\/li>\n\n\n\n
                • Specialty products<\/li>\n<\/ul>\n\n\n\n

                  It has also strengthened its research capabilities over time.<\/p>\n\n\n\n

                  This diversification strategy helps reduce dependency on a single product category or market.<\/p>\n\n\n\n

                  Investor Sentiment Around Pharma Stocks<\/strong><\/h2>\n\n\n\n

                  Pharmaceutical stocks often attract investors during periods of economic uncertainty because healthcare demand tends to remain relatively stable compared to cyclical industries.<\/p>\n\n\n\n

                  However, pharma investing is also influenced by:<\/p>\n\n\n\n

                    \n
                  • Regulatory developments<\/li>\n\n\n\n
                  • Product approvals<\/li>\n\n\n\n
                  • Patent expiries<\/li>\n\n\n\n
                  • Global healthcare trends<\/li>\n<\/ul>\n\n\n\n

                    Buyback announcements can therefore provide an additional positive trigger in the sector.<\/p>\n\n\n\n

                    Opportunities Emerging From the Buyback<\/strong><\/h2>\n\n\n\n

                    The Zydus Lifesciences share buyback creates several opportunities.<\/p>\n\n\n\n

                    Short-Term Trading Opportunities<\/strong><\/h3>\n\n\n\n

                    Stocks often witness increased momentum around:<\/p>\n\n\n\n

                      \n
                    • Buyback announcements<\/li>\n\n\n\n
                    • Record dates<\/li>\n\n\n\n
                    • Tender periods<\/li>\n<\/ul>\n\n\n\n

                      This may create short-term trading opportunities for active market participants.<\/p>\n\n\n\n

                      Long-Term Investment Confidence<\/strong><\/h3>\n\n\n\n

                      Management deploying cash toward buybacks may strengthen investor confidence in the company\u2019s long-term outlook.<\/p>\n\n\n\n

                      Improved Financial Ratios<\/strong><\/h3>\n\n\n\n

                      Reduced share count can positively impact:<\/p>\n\n\n\n

                        \n
                      • Earnings per share<\/li>\n\n\n\n
                      • Return on equity<\/li>\n\n\n\n
                      • Capital efficiency ratios<\/li>\n<\/ul>\n\n\n\n

                        Risks Investors Should Consider<\/strong><\/h2>\n\n\n\n

                        Despite the positive sentiment, there are risks that investors should evaluate carefully.<\/p>\n\n\n\n

                        Partial Acceptance Risk<\/strong><\/h3>\n\n\n\n

                        Not all shares tendered in a buyback may be accepted.<\/p>\n\n\n\n

                        Oversubscription can reduce actual gains for shareholders.<\/p>\n\n\n\n

                        Market Volatility<\/strong><\/h3>\n\n\n\n

                        Stock prices may fluctuate sharply before and after the buyback process.<\/p>\n\n\n\n

                        Sector-Specific Risks<\/strong><\/h3>\n\n\n\n

                        Regulatory issues, pricing pressure, or weak export demand can impact pharmaceutical companies.<\/p>\n\n\n\n

                        Valuation Concerns<\/strong><\/h3>\n\n\n\n

                        Investors should avoid making decisions solely based on buyback announcements without considering overall business fundamentals.<\/p>\n\n\n\n

                        How Buybacks Compare With Dividends<\/strong><\/h2>\n\n\n\n

                        Many investors compare buybacks and dividends as shareholder reward mechanisms.<\/p>\n\n\n\n

                        Dividends<\/strong><\/h3>\n\n\n\n
                          \n
                        • Provide direct cash payouts<\/li>\n\n\n\n
                        • Offer predictable income<\/li>\n\n\n\n
                        • Are taxed differently<\/li>\n<\/ul>\n\n\n\n

                          Buybacks<\/strong><\/h3>\n\n\n\n
                            \n
                          • Reduce outstanding shares<\/li>\n\n\n\n
                          • May improve EPS<\/li>\n\n\n\n
                          • Can support stock prices<\/li>\n<\/ul>\n\n\n\n

                            Companies choose between these options based on capital allocation priorities and business conditions.<\/p>\n\n\n\n

                            What Analysts May Watch Next<\/strong><\/h2>\n\n\n\n

                            After the buyback announcement, analysts are expected to monitor:<\/p>\n\n\n\n

                              \n
                            • Shareholder participation levels<\/li>\n\n\n\n
                            • Acceptance ratio<\/li>\n\n\n\n
                            • Future earnings growth<\/li>\n\n\n\n
                            • R&D pipeline progress<\/li>\n\n\n\n
                            • US market performance<\/li>\n\n\n\n
                            • Margin trends<\/li>\n<\/ul>\n\n\n\n

                              Long-term investor sentiment will likely depend more on operational performance than the buyback itself.<\/p>\n\n\n\n

                              The Bigger Picture for Indian Equity Markets<\/strong><\/h2>\n\n\n\n

                              Buyback activity across Indian companies has increased in recent years.<\/p>\n\n\n\n

                              Many firms with strong balance sheets are using buybacks to:<\/p>\n\n\n\n

                                \n
                              • Reward shareholders<\/li>\n\n\n\n
                              • Improve capital structure<\/li>\n\n\n\n
                              • Signal confidence<\/li>\n<\/ul>\n\n\n\n

                                This trend reflects the growing maturity of India\u2019s corporate and capital market ecosystem.<\/p>\n\n\n\n

                                For investors, however, it remains important to distinguish between companies using buybacks strategically and those using them primarily for short-term market sentiment.<\/p>\n\n\n\n

                                Conclusion<\/strong><\/h2>\n\n\n\n

                                The \u20b91,100 crore share buyback announcement by Zydus Lifesciences has generated strong investor interest because of its attractive 13% premium and positive implications for shareholder value.<\/p>\n\n\n\n

                                Beyond the immediate market excitement, the development highlights the company\u2019s strong cash position, management confidence, and focus on efficient capital allocation. The tender offer route also gives retail investors an opportunity to participate directly in the buyback process.<\/p>\n\n\n\n

                                At the same time, investors should evaluate broader business fundamentals, pharmaceutical sector risks, and acceptance ratio dynamics before making decisions.<\/p>\n\n\n\n

                                As India\u2019s pharmaceutical sector continues evolving through innovation, exports, and healthcare expansion, companies like Zydus Lifesciences are expected to remain closely tracked by both institutional and retail investors.<\/p>\n\n\n\n

                                The buyback may act as a short-term catalyst, but the company\u2019s long-term growth trajectory will ultimately depend on execution, regulatory compliance, product pipeline strength, and global market performance.<\/p>\n\n\n\n

                                Frequently Asked Questions (FAQs)<\/strong><\/h2>\n\n\n\n

                                1. What is the Zydus Lifesciences share buyback?<\/strong><\/h3>\n\n\n\n

                                It is a \u20b91,100 crore share repurchase program announced by Zydus Lifesciences through the tender offer route.<\/p>\n\n\n\n

                                2. What is the buyback price offered by Zydus Lifesciences?<\/strong><\/h3>\n\n\n\n

                                The company announced the buyback at around a 13% premium over the prevailing market price.<\/p>\n\n\n\n

                                3. Why did Zydus announce a buyback?<\/strong><\/h3>\n\n\n\n

                                The buyback aims to improve shareholder value and optimize capital allocation.<\/p>\n\n\n\n

                                4. What is the record date for the Zydus buyback?<\/strong><\/h3>\n\n\n\n

                                The record date determines shareholder eligibility for participating in the buyback offer.<\/p>\n\n\n\n

                                5. What is a share buyback?<\/strong><\/h3>\n\n\n\n

                                A share buyback occurs when a company repurchases its own shares from shareholders.<\/p>\n\n\n\n

                                6. How does a buyback benefit investors?<\/strong><\/h3>\n\n\n\n

                                Investors may get an opportunity to tender shares at a premium price.<\/p>\n\n\n\n

                                7. What is the tender offer route in buybacks?<\/strong><\/h3>\n\n\n\n

                                Under this route, eligible shareholders can directly offer shares back to the company.<\/p>\n\n\n\n

                                8. Will all tendered shares be accepted?<\/strong><\/h3>\n\n\n\n

                                Not necessarily. Acceptance depends on entitlement ratios and oversubscription levels.<\/p>\n\n\n\n

                                9. What is the acceptance ratio in a buyback?<\/strong><\/h3>\n\n\n\n

                                It is the percentage of tendered shares actually accepted by the company.<\/p>\n\n\n\n

                                10. How does a buyback affect earnings per share?<\/strong><\/h3>\n\n\n\n

                                Reducing outstanding shares can improve EPS if profits remain stable.<\/p>\n\n\n\n

                                11. Is Zydus Lifesciences a pharmaceutical company?<\/strong><\/h3>\n\n\n\n

                                Yes, it is a major Indian pharmaceutical and healthcare company.<\/p>\n\n\n\n

                                12. What businesses does Zydus Lifesciences operate in?<\/strong><\/h3>\n\n\n\n

                                The company operates in generics, specialty drugs, vaccines, biosimilars, and consumer healthcare.<\/p>\n\n\n\n

                                13. Why do investors track buyback premiums?<\/strong><\/h3>\n\n\n\n

                                Premiums indicate the additional value offered above current market prices.<\/p>\n\n\n\n

                                14. Can buybacks support stock prices?<\/strong><\/h3>\n\n\n\n

                                Yes, buybacks often improve investor sentiment and may support stock prices.<\/p>\n\n\n\n

                                15. What risks should investors consider in buybacks?<\/strong><\/h3>\n\n\n\n

                                Oversubscription, market volatility, and business risks should be considered.<\/p>\n\n\n\n

                                16. How is a buyback different from dividends?<\/strong><\/h3>\n\n\n\n

                                Dividends provide direct payouts, while buybacks reduce outstanding shares.<\/p>\n\n\n\n

                                17. Why is the pharmaceutical sector important in India?<\/strong><\/h3>\n\n\n\n

                                India is a major global supplier of generic medicines and healthcare products.<\/p>\n\n\n\n

                                18. What are the key risks for pharmaceutical companies?<\/strong><\/h3>\n\n\n\n

                                Regulatory issues, pricing pressure, and currency fluctuations are major risks.<\/p>\n\n\n\n

                                19. Does Zydus Lifesciences have global operations?<\/strong><\/h3>\n\n\n\n

                                Yes, the company operates across several international markets.<\/p>\n\n\n\n

                                20. What should investors watch after the buyback announcement?<\/strong><\/h3>\n\n\n\n

                                Investors should monitor participation levels, acceptance ratios, earnings growth, and business performance.<\/p>\n\n\n\n

                                Disclaimer Note: The securities quoted, if any, are for illustration only and are not recommendatory. This article is for education purposes only and shall not be considered as a recommendation or investment advice by Equentis. We will not be liable for any losses that may occur. Investments in the securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI, membership of BASL & certification from NISM in no way guarantee the performance of the intermediary or provide any assurance of returns to investors.<\/p>\n","protected":false},"excerpt":{"rendered":"

                                Summary Zydus Lifesciences has announced a \u20b91,100 crore share buyback at a 13% premium to the prevailing market price, attracting […]<\/p>\n","protected":false},"author":25,"featured_media":67127,"comment_status":"closed","ping_status":"0","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[948],"tags":[],"class_list":["post-67124","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-stock-market-news"],"_links":{"self":[{"href":"https:\/\/www.equentis.com\/blog\/wp-json\/wp\/v2\/posts\/67124","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.equentis.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.equentis.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.equentis.com\/blog\/wp-json\/wp\/v2\/users\/25"}],"replies":[{"embeddable":true,"href":"https:\/\/www.equentis.com\/blog\/wp-json\/wp\/v2\/comments?post=67124"}],"version-history":[{"count":1,"href":"https:\/\/www.equentis.com\/blog\/wp-json\/wp\/v2\/posts\/67124\/revisions"}],"predecessor-version":[{"id":67130,"href":"https:\/\/www.equentis.com\/blog\/wp-json\/wp\/v2\/posts\/67124\/revisions\/67130"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.equentis.com\/blog\/wp-json\/wp\/v2\/media\/67127"}],"wp:attachment":[{"href":"https:\/\/www.equentis.com\/blog\/wp-json\/wp\/v2\/media?parent=67124"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.equentis.com\/blog\/wp-json\/wp\/v2\/categories?post=67124"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.equentis.com\/blog\/wp-json\/wp\/v2\/tags?post=67124"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}